Intercept Pharmaceuticals, Inc. (ICPT)

FromSY investing:
Cantor 2020 #biotech outlook

Top picks:
- Large-cap: $VRTX $AMGN
- Mid-cap: $SRPT $ALNY
- Small-cap: $TGTX $ICPT $GBT $AGIO
- Favorite binary: $MYOK

from Andrew Dunn:
Top takeout targets, per new Credit Suisse investor survey:
1. $CLVS
2. $SRPT
3. $ALDR
4. $INCY
5. $BMRN
6. $GLPG
7. $ALXN
8. $IMMU
9. $ICPT
10. $VKTX

https://seekingalpha.com/article/4357247-intercepts-pain-is-galectins-gain-clinical-outcomes-in-nash-are-crucial?v=1594125019&comments=show

Intercept's Pain Is Galectin's Gain: Clinical Outcomes In NASH Are Crucial

$GALT $ICPT $GNFT

From stocktwits forum:
12/24/21, 06:39 AM
$ICPT
, $ 80 to $ 100 with positive Phase 3 results or $ 12 to $ 15 with failed trial. Unbelievably favorable Risk-Reward ratio. With 40 % short ratio. Load up guys.

Sold other than 300 stock. They are profit only and will hold forever. Lately I am exiting most of my biotech.

I still hold them in my IRA but no more regular account.
Here is list of biotech I give up hope.
1.> $AMRN
2.> $BLUE
3.> $MDGL
4.> $ICPT
5.> $PBYI
6.> $CLVS (Only sold half before their disaster offering tank stock. HOlding to see if we get combo trial result boost. But may exit as well.)
7.> NKTR (Half)
8.> AERI ( Half)

I am holding very large GILD (3000) and MRNA (3000). Sure I am shorting some high flyer so part of reason to sell is get buying power to I can hold or short more on those. Some day they will print solid profit but right now anything I touch on short, it start flying high and only stop if give up.

Most Shorted Stocks According To S3
$CRTX – SI 58%
$PPSI – SI 47%
$GREE – SI 45%
$IFMK – SI 45%
$BYND – SI 39%
$IMUN – SI 38%
$BLNK – SI 37%
$ICPT – SI 35%
$BYSI – SI 33%
$ESPR – SI 33%
$BEEM – SI 33%
$LMND – SI 33%

Stocks with the highest short interest
$BFRI – SI 83%
$CRTX – SI 55%
$IMUN – SI 41%
$LGVN – SI 38%
$ICPT – SI 35%
$SAVA – SI 35%
$PRLD – SI 35%
$BLNK – SI 35%
$LMND – SI 35%
$WEBR – SI 34%
$RELI – SI 34%

"The phase 2 study has the surrogate and primary endpoint as HVPG - Hepatic venous pressure gradient. so if in Q4 2018 the phase 2 endpoint HVPG is met, then accelerated approval is possible without the need to run a phase 3 for approval."

"the phase 2a pilot study for portal hypertension Conatus achieved a 92% response rate 11 out of 12 patients responding after only 4 weeks of treatment with emricasan given 25 mg twice daily."

CNAT the next to report NASH Cirrhosis PH Phase 2b/3 at 5MG, 25MG, 50MG twice daily... if GOOD likely FDA approval... Trial data in or before Q4 2018.

NASH $GALT $VKTX $GLMD $MDLG $ICPT

Still at 83% so not much covering took place. Let's do some more frying.

Stocks with the highest short interest
$BFRI – SI 83%
$CRTX – SI 55%
$IMUN – SI 41%
$LGVN – SI 38%
$ICPT – SI 35%
$SAVA – SI 35%
$PRLD – SI 35%

Bio Ph 2 & Ph 3 Data Readouts Feb

$SWTX Ph 3
$ADAG Ph 2
$ICPT Ph 3
$IMMP Ph 2
$VERU Ph 2
$DMAC Ph 2
$KLDO Ph 2
$MREO Ph 2
$SLS Ph 2
$CORT Ph 2
$CRBP Ph 2
$PRAX Ph 2
$AMRN Ph 2
$ZEAL Ph 3
$CBAY Ph 2
$ARVN Ph 2
$TNXP Ph 3
$FGEN Ph 2

Catalyst Calendar => http://bpiq.com/fda-catalyst-calendar